InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.17
(
-0.25%
)
US TECH 100
19,245.60
(
-0.07%
)
Dow Jones
39,134.76
(
0.77%
)
Brent Oil
84.99
(
-0.02%
)
Bitcoin
64,050.21
(
-1.19%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

jaybe

Send PM Follow Ignore
Followers 5
Posts 277
Boards Moderated 0
Alias Born 05/29/2011

jaybe

Re: None

Friday, 06/28/2013 10:21:56 PM

Friday, June 28, 2013 10:21:56 PM

Post# of 80490
"Game Over" for Synribo in CML....

Not that anyone was worried about Synribo, but these results make you wonder why they (Teva via Cephalon via ChemGenex)kept pursuing trials, approval, and sales after Pona data in mid-2011 left absolutely no margin for success.

Results reported June 17th from a study of Synribo(omacetaxine) in CML with 2 or more prior TKI's compared to Pona (PACE):

MCyR of 20% vs. Pona 64%

Grade 3/4 AE's:
Thrombocytopenia 67% vs. Pona 34%
Neutropenia 47% vs. Pona 16%
Anemia 37% vs. Pona 8%

Weaker and more toxic? As HB would say...game over.

http://www.ncbi.nlm.nih.gov/pubmed/23787123
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up